Companies › CSPC Megalith Biopharmaceutical
8 active drug programs in 13 registered trials: 6 Phase 1, 5 Phase 2, 2 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SYS6043 B7-H3-targeted antibody-drug conjugate | B7H3 | Phase 3 | Platinum-resistant Ovarian Cancer; Advanced/Metastatic Solid Tumors | Dec 2027 |
| SYS6010 | – | Phase 3 | EGFR-mutated Locally Advanced or Metastatic NSCLC; Head and Neck Squamous Cell Carcinoma | Jun 2028 |
| SYS6041 anti-FOLR1 antibody-drug conjugate | FOLR1 | Phase 2 | Ovarian Cancer; Advanced Solid Tumors | Mar 2027 |
| SYS6023 | – | Phase 2 | Advanced Breast Cancer; Advanced Solid Tumor | Nov 2027 |
| Enlonstobart recombinant human anti-PD-1 monoclonal antibody | PDCD1 | Phase 2 | Ovarian Cancer; Head and Neck Squamous Cell Carcinoma | Apr 2028 |
| SYS6005 | – | Phase 1 | B-cell Malignancies | Jan 2027 |
| SYS6040 for injection | – | Phase 1 | Small Cell Lung Cancer | Feb 2027 |
| SYS6045 HER2-targeted therapy | ERBB2 | Phase 1 | Advanced Solid Tumors | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06927986 | SYS6010 | Phase 3 | EGFR-mutated Locally Advanced or Metastatic NSCLC | Oncology | Jul 2026 |
| NCT06958679 | SYS6005 | Phase 1 | B-cell Malignancies | Oncology | Jan 2027 |
| NCT06970795 | SYS6040 for injection | Phase 1 | Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT07744763 | SYS6041 | Phase 1 | Advanced Solid Tumors | Oncology | Mar 2027 |
| NCT07122063 | SYS6045 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2027 |
| NCT07597629 | SYS6023 | Phase 2 | Advanced Breast Cancer | Oncology | Nov 2027 |
| NCT07415863 | SYS6043 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Dec 2027 |
| NCT07714668 | Enlonstobart | Phase 2 | Ovarian Cancer | Oncology | Apr 2028 |
| NCT07714668 | SYS6041 | Phase 2 | Ovarian Cancer | Oncology | Apr 2028 |
| NCT07254585 | SYS6010 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Jun 2028 |
| NCT07254585 | Enlonstobart | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Jun 2028 |
| NCT07110883 | SYS6023 | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2028 |
| NCT07708753 | SYS6043 | Phase 3 | Platinum-resistant Ovarian Cancer | Oncology | Oct 2029 |
DualityBio RemeGen CStone Pharmaceuticals Shenyang Sunshine Pharmaceutical TaiRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.